Owing to recent advances in mass spectrometry (MS), tens to hundreds of proteins, lipids,
and small molecules can be measured in single cells. The ability to characterize the …

Single-cell RNA-sequencing methods are now robust and economically practical and are
becoming a powerful tool for high-throughput, high-resolution transcriptomic analysis of cell …

Background Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive
hematologic cancer that is caused by transformed plasmacytoid dendritic cells that …

The safety and efficacy of combining the isocitrate dehydrogenase-1 (IDH1) inhibitor
ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO+ VEN)±azacitidine (AZA; …

Tumour heterogeneity refers to the fact that different tumour cells can show distinct
morphological and phenotypic profiles, including cellular morphology, gene expression …

MCL-1 and BCL-2 are both frequently overexpressed in acute myeloid leukemia (AML) and
critical for the survival of AML cells and AML stem cells. MCL-1 is a key factor in venetoclax …

BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia
(CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy …

Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) represent a low-frequency
subpopulation of leukemia cells that possess stem cell properties distinct from the bulk …

The pathogenesis of acute myeloid leukemia (AML) involves serial acquisition of mutations
controlling several cellular processes, requiring combination therapies affecting key …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically challenging
hematologic malignancy with dismal outcomes. With a median age of∼ 70 years, the …